Hormonal
Common genetic variants in genes primarily influencing pancreatic beta-cell function (specifically ABCC8, KCNJ11, SLC2A2, HNF4A, and INS) significantly alter the risk of developing Type 2 diabetes.
If you have a family history of Type 2 diabetes, you likely carry genetic variants that affect how your pancreas secretes insulin or how your cells respond to it. This is not a life sentence, but it is a biological reality. You may need to be more vigilant with diet and exercise than someone without this genetic load to maintain healthy blood sugar levels, as your body may have less reserve in beta-cell function.
Polymorphisms in five of 15 genes (33%) encoding molecules known to primarily influence pancreatic b-cell function—ABCC8 (sulphonylurea receptor), KCNJ11 (KIR6.2), SLC2A2 (GLUT2), HNF4A (HNF4a), and INS (insulin)—significantly altered disease risk
Why this rating
Large-scale candidate gene association study with 2,134 subjects and independent quantitative trait validation.
Source
Candidate Gene Association Study in Type 2 Diabetes Indicates a Role for Genes Involved in β-Cell Function as Well as Insulin Action
Inês Barroso et al. · PLoS Biology · 2003
DOI 10.1371/journal.pbio.0000020
More from this paper
- Common variants in genes primarily influencing insulin action (specifically INSR, PIK3R1, and SOS1) are significantly associated with Type 2 diabetes risk.Good
- Common variants in genes influencing pancreatic beta-cell function make a significant contribution to the inherited component of Type 2 diabetes, often with small individual effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →